



800 E. 28th Street  
Minneapolis, MN 55407-3799  
612-863-4000

**2023**  
**Abbott Northwestern Hospital**  
**Antimicrobial Susceptibilities**  
**of Major Pathogens**

- The intent of this document is to provide a preliminary guide to susceptibilities. This information should be used together with the specific susceptibility results of the isolated organism and guidelines from current publications. This report summarizes routinely tested antibiotics. Actual patient reports may not include all antimicrobials listed in the tables.
- Results are from inpatients only and include only one isolate per patient.
- Isolates collected from Emergency Department visits are included in the inpatient antibiogram.
- MRSA and VRE surveillance culture isolates are not included.
- All intermediate (I) interpretations are included in the resistant category.
- All organisms identified, excluding blood culture isolates, are held for a period of 7 days after the final report is issued. Blood culture isolates are held for 1 month. Testing of additional antimicrobials is available upon request.

**For further information, contact:**

Brenda Katz, MD, Pathologist,  
[Brenda.Katz@allina.com](mailto:Brenda.Katz@allina.com), 612-863-4708

ABBOTT NORTHWESTERN HOSPITAL-2023 ANTIMICROBIAL SUSCEPTIBILITIES

GRAM NEGATIVE BACILLI	Isolates														
		AMPICILLIN	AMPICILLIN/SULBACTAM	CEFZOLIN-UC*	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	LEVOFLOXACIN	MEROPENEM	NITROFURANTOIN <sup>u</sup>	PIPERACILLIN/TAZO	TOBRAMYCIN	TRIMETHOPRIM/SULFA
<i>Acinetobacter</i> species (all combined)	39		97		100	76		92	97	94	94		61	92	94
<i>Citrobacter</i> species (all combined)	120				100	78	76	96	96	95	98	91	80	99	95
<i>Enterobacter</i> species (all combined)	189				95	73	68	93	96	88	100	40	70	95	93
<i>Escherichia coli</i>	1220	53	65	86	90	89	89	75	92	72	100	96	95	92	75
<i>Klebsiella aerogenes</i> (formerly <i>Ent. aerogenes</i> )	64				96	79	79	98	100	95	98	34	79	98	96
<i>Klebsiella oxytoca</i>	106		65		98	97	95	98	100	98	100	92	92	99	97
<i>Klebsiella pneumoniae</i>	345		86	91	92	92	91	89	97	85	100	33	96	97	90
<i>Klebsiella variicola</i>	43		97		100	100	100	100	97	97	100	82	97	97	100
<i>Morganella morganii</i>	57		12		92	78	91	87	98	87	98		98	96	89
<i>Proteus mirabilis</i>	196	84	89	95	97	97	96	84	92	84	100		100	93	84
<i>Pseudomonas aeruginosa</i>	301				89	90		82	96	77	89		87	98	
<i>Serratia marcescens</i>	49				97	97	97	97	100	95	97			91	100
<i>Stenotrophomonas maltophilia</i>	60					33				91					83

\* Cefazolin-UC; the % susceptible can only be ascertained on isolates of *E.coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* from uncomplicated UTIs. The cefazolin threshold for susceptible is <= 2 µg/ml for all other sources and Enterobacterales. The lowest dilution for cefazolin on the Allina FDA cleared automated platform is 4 µg/ml, thus no susceptible results can be determined by this method.

>90% Susceptible
61-89% Susceptible
0-60% Susceptible

GRAM POSITIVE COCCI	ISOLATES																							
		AMPICILLIN	AZITHROMYCIN	CEFZOLIN	CEFTRIAXONE	CEFTRIAXONE-IV-MENINGITIS <sup>2</sup>	CEFTRIAXONE-IV-NONMENINGITIS <sup>2</sup>	CLARITHROMYCIN	CLINDAMYCIN	DAPTOMYCIN <sup>4</sup>	DOXYCYCLINE	ERYTHROMYCIN	GENTAMICIN <sup>5</sup>	LEVOFLOXACIN	LINEZOLID	NITROFURANTOIN <sup>u</sup>	OXACILLIN	PENICILLIN	PENICILLIN-IV-MENINGITIS <sup>6</sup>	PENICILLIN-IV-NONMENINGITIS <sup>6</sup>	RIFAMPIN <sup>8</sup>	TRIMETHOPRIM/SULFA	VANCOMYCIN	
<i>Enterococcus faecalis</i>	531	99						70				85 <sup>u</sup>	100	99		99								99
<i>Enterococcus faecium</i>	83	27						84 <sup>1</sup>				25 <sup>u</sup>	100	21	32									57
<i>Staph. aureus</i>	871		66					79	100	97	55	98	76	100	100	66					99	92	100	
<i>Staphylococcus Coag Negative</i>	204		44					60	98	92	47	89	72	100	96	44					99	65	100	
<i>Staph. lugdunensis</i>	73		90					78	100	100	79	100	97	100	100	90					100	100	100	
<i>Strep. agalactiae</i> (Strep Group B)	64	100		100				46			39		98	100			100							100
<i>Strept. dysgalactiae</i>	39	100		100				48			46		100	100			100							100
<i>Strep. pneumoniae</i> **	36		66		91	100	66										69	100	69		75			100
<i>Strep. pyogenes</i> (Beta Strep group A)	69	100		100				95			91		95	100			100							100

<sup>U</sup> Reported on urine isolates only.

<sup>1</sup> Daptomycin does not have recognized breakpoints for *E. faecium*. Susceptibilities reported in this antibiogram are based on the susceptible dose dependent (SDD) MIC  $\leq 4$   $\mu\text{g/mL}$  using an 8-12 mg/kg daily regimen. Infectious Disease consultation is recommended prior to utilizing daptomycin to cover *E. faecium*.

<sup>2</sup> Ceftriaxone - IV meningitis susceptible MIC  $\leq 0.5$   $\mu\text{g/mL}$ .

<sup>3</sup> Ceftriaxone - IV non-meningitis susceptible MIC  $\leq 1$   $\mu\text{g/mL}$ .

<sup>4</sup> Daptomycin not reported on isolates from respiratory tract.

<sup>5</sup> Gentamicin should not be used as monotherapy for gram positive infections.

<sup>6</sup> Penicillin - Oral and IV meningitis susceptible MIC  $\leq 0.06$   $\mu\text{g/mL}$

<sup>7</sup> Penicillin - IV nonmeningitis susceptible MIC  $\leq 2$   $\mu\text{g/mL}$ .

<sup>8</sup> Rifampin should not be used alone for antimicrobial therapy.

\*\* *S. pneumoniae* isolate distribution by specimen type; 22% blood, 67% respiratory, 0% spinal fluid, 11% other specimen types.

## Links to Related Content

[Allina Health Laboratory](#)

[Organism Groupings of Routinely Test Antimicrobials at Allina Health Laboratory](#)

[Allina Health Antimicrobial Susceptibility Data](#)

[2024 Allina Health Antimicrobials Costs](#)

[Pharmacy Services](#)

[Antimicrobial Stewardship](#)